高胆固醇血症与他汀暴露对大型全国肝硬化队列患者生存的影响
该回顾性队列研究纳入2008年1月1日至2016年6月30日退伍军人健康管理局新诊断肝硬化患者,分为既往他汀暴露者21,921例与他汀未暴露者51,023例(其中新启动者8,794例、未启动者44,269例)。他汀未暴露者基线总胆固醇每升高10 mg/dL与死亡率降低3.6%相关;既往使用者每继续暴露他汀一年死亡风险比为0.920(95%CI 0.897-0.943),新启动者每暴露一年为0.913(95%CI 0.890-0.937)。结论认为高胆固醇血症与肝功能保持良好及死亡率降低相关,Child-Turcotte-Pugh A和B级肝硬化患者每累积一年他汀暴露与死亡率独立降低8.0%-8.7%相关。
要点
- 他汀未暴露者基线总胆固醇每升高10 mg/dL与死亡率降低3.6%相关。
- 既往他汀使用者每继续暴露一年死亡风险比为0.920(95%CI 0.897-0.943)。
- 新启动他汀者每暴露一年死亡风险比为0.913(95%CI 0.890-0.937)。
核心结论
- 在新诊断肝硬化的退伍军人回顾性队列中,高胆固醇血症与肝功能保持良好及死亡率降低相关。
- Child-Turcotte-Pugh A和B级肝硬化患者每累积一年他汀暴露与死亡率独立降低8.0%-8.7%相关。
研究设计与样本
- 回顾性队列研究,纳入2008年1月1日至2016年6月30日退伍军人健康管理局新诊断肝硬化患者。
- 既往他汀暴露者21,921例;他汀未暴露者51,023例,其中新启动他汀者8,794例、未启动者44,269例。
- 采用逆概率加权的多变量Cox比例风险模型评估时间更新血脂谱和他汀累积暴露对生存及肝功能失代偿的影响。
- 他汀未暴露的新启动者与未启动者进行倾向性匹配以模拟随机对照试验。
主要发现
- 他汀未暴露者基线总胆固醇每升高10 mg/dL与死亡率降低3.6%相关。
- 既往使用者每继续暴露他汀一年死亡风险比为0.920(95%CI 0.897-0.943)。
- 风险集匹配后,新启动者每暴露他汀一年死亡风险比为0.913(95%CI 0.890-0.937)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Concerns related to hepatotoxicity frequently lead to discontinuation or non-initiation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase therapy in patients with cirrhosis despite data supporting statin use. We investigated the independent effects of hyperlipidemia and statin exposure on mortality, hepatic decompensation, and hepatocellular carcinoma development in a large national cohort of patients with cirrhosis. METHODS: We performed a retrospective cohort study of patients with newly diagnosed cirrhosis from January 1, 2008 through June 30, 2016 in the Veterans Health Administration. Subjects were divided into 2 cohorts: 21,921 patients with prior statin exposure (existing users) and 51,023 statin-naïve individuals, of whom 8794 subsequently initiated statin therapy (new initiators) and 44,269 did not (non-initiators). Multivariable Cox proportional hazard models with inverse probability weighting were constructed to assess the effects of time-updating lipid profiles and cumulative exposure to statins on survival and hepatic decompensation. Statin-naïve new initiators were propensity matched with non-initiators to simulate a randomized controlled trial of statin use in cirrhosis. RESULTS: In statin-naïve subjects, every 10-mg/dL increase in baseline total cholesterol was associated with a 3.6% decrease in mortality. In existing users, each year of continued statin exposure was associated with a hazard ratio of 0.920 (95% confidence interval 0.0.897-0.943) for mortality. After risk-set matching, each year of statin exposure among new initiators was associated with a hazard ratio of 0.913 (95% confidence interval 0.890-0.937) for mortality. CONCLUSIONS: In a retrospective cohort study of veterans with a new diagnosis of cirrhosis, we associated hypercholesterolemia with well-preserved hepatic function and decreased mortality. Nonetheless, each cumulative year of statin exposure was associated with an independent 8.0%-8.7% decrease of mortality of patients with cirrhosis of Child-Turcotte-Pugh classes A and B.
引用
- Kaplan DE, Serper MA, Mehta R, et al. Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis. Gastroenterology. 2019. PMID: 30660733. doi:10.1053/j.gastro.2019.01.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。